Abstract:Background: There have been several recent advances in the care of patients with chronic kidney disease (CKD), including the use of sodium glucose cotransporter 2 (SGLT2) inhibitors and selective mineralocorticoid receptor antagonists (MRAs). There are very few data reporting the outcomes of these treatments in real-world experience. The aim of this retrospective study is to report the effects of SGLT2 inhibitors, finerenone, and their combination in CKD patients in our community-based setting. Methods: Ninety-eight patients with CKD with an estimated glomerular filtration rate (eGFR) between 25 and 90 mL/min per 1.73 m2 and a urine albumin-to-creatinine ratio (UACR) ≥ 30 mg/g were included. Patients were divided into three groups: two monotherapy groups of SGLT2 inhibitors or finerenone and a third combination group of therapy with SGLT2 inhibitors for the first 4 months and SGLT2 inhibitors and finerenone subsequently. The primary outcomes were the timing and percentage of patients achieving a >50% reduction in UACR from baseline. Results: Group 1 comprised 52 patients on SGLT2i, group 2 had 22 patients on finerenone, and group 3 had 24 patients on combination therapy. The baseline median UACR and mean eGFR were 513 mg/g and 47.9 mL/min per 1.73 m2 in group 1, 548.0 mg/g and 50.5 mL/min per 1.73 m2 in group 2, and 800 mg/g and 60 mL/min per 1.73 m2 in group 3. At baseline, 71 (72.4%) patients were on the angiotensin-converting enzyme inhibitor (ACEi) or the angiotensin receptor blocker (ARB), and 78 (79.5%) patients had type 2 diabetes. After 8 months of follow-up, a >50% decrease in albuminuria was achieved in 96% of patients in group 3, compared to 50% in group 1 and 59% in group 2 (p-values were <0.01 and <0.01, respectively). There was a statistically but not clinically significant change in mean potassium levels in group 2 (+0.4 mmol/L) compared to either group 1 (0.0 mmol/L with p-value: <0.01) or group 3 (−0.01 mmol/L with p-value: <0.01). However, there was no difference in potassium levels when comparing groups 1 and 3. At the end of the follow-up, the average difference in eGFR was −3.4 (8.8), −5.3(10.1), and −7.8 (11.2) mL/min per 1.73 m2 in groups 1, 2, and 3, respectively, without a statistically significant difference between groups. Conclusions: In this real-world experience in our community setting, the combination of SGLT2 inhibitors and finerenone in our adult patients with CKD was associated with a very significant and clinically relevant reduction in UACR, without an increased risk of hyperkalemia. Combination therapy of SGLT2 inhibitor and finerenone regarding background use of ACEi/ARB is feasible and should be encouraged for further albuminuria reductions in CKD patients.

Effects of allisartan‐isoproxil‐based combination antihypertensive regimen in hypertensive patients with microalbuminuria or hyperuricemia

Influence of valsartan on Microalbuminuria of Essential Hypertensive Patients

EFFECT OF DIFFERENT ANTIHYPERTENSIVE STRATEGIES ON THE MICROALBUMINURIA EXCRETION

Effects and Safety of Allisartan Isoproxil Combined with Amlodipine or Indapamide in Patients with Hypertension Who Failed Allisartan Monotherapy

Effect of telmisartan on microalbuminuria in patients with hypertension

Efficacy and Safety of the Compound of Candesartan Cilexetial and Hydrochlorothiazide in Patients with Essential Hypertension

Aliskiren Therapy in Hypertension and Cardiovascular Disease: a Systematic Review and a Meta-Analysis

Efficacy of Allisartan Isoproxil in the Treatment of Mild-to-Moderate Essential Hypertension.

The Effect of Losartan on Microalbuminuria in the Treatment of Early Stage of Diabetic Nephropathy Independent of Blood Pressure

Effect Of Uric Acid-Lowering Therapy On Blood Pressure: Systematic Review And Meta-Analysis

P2643Antiproteinuric efficacy of ACE inhibitors, selective MRAs and ACE inhibitor/selective MRA combination therapy in diabetic hypertensives with microalbuminuria

Efficacy and safety evaluation of Allisartan Isoproxil in patients with hypertension: a meta-analysis

Efficacy and Safety of Valsartan in Reducing Blood Pressure and Albuminuria in Chinese Patients with Essential Hypertension: a Multicenter Prospective Open-Label Observational Study

Relationship Between Microalbuminuria and Apelin in Primary Hypertensive Patients

Association Between Change in Central Nocturnal Blood Pressure and Urine Albumin-Creatinine Ratio by a Valsartan/Amlodipine Combination: A CPET Study

PS 17-77 A RANDOMIZED, DOUBLE-BLIND AND DOUBLE-DUMMY, MULTIPLE-DOSE, POSITIVE AND PARALLEL COMPARATIVE, MULTICENTER CLINICAL TRIAL OF ALLISARTAN EVALUATE EFFICACY AND SAFETY IN PATIENTS WITH MILD TO MODERATE ESSENTIAL HYPERTENSION

Synergistic Effects of Yiqi Huazhuo Gushen Herbal Formula and Valsartan on Metabolic Syndrome Complicated with Microalbuminuria

Impact of irbesartan, an angiotensin receptor blocker, on uric acid level and oxidative stress in high-risk hypertension patients

Effect of two antihypertensive combinations on metabolic control in type-2 diabetic hypertensive patients with albuminuria: a randomised, double-blind study

Effect Different Medicine on Serum Uric Acid in Patients with Hypertension

Real-Life Experience on the Effect of SGLT2 Inhibitors vs. Finerenone vs. Combination on Albuminuria in Chronic Kidney Disease